UCB
UCB.BR Large CapHealthcare · Biotechnology
Updated: Aug 20, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and a
UCB Stock at a Glance
UCB (UCB.BR) is currently trading at €217.90 with a market capitalization of $41.5B. The trailing P/E ratio stands at 19.23x, with a forward P/E of 15.64x. The 52-week range spans from €191.20 to €289.50; the current price is 24.7% below the yearly high. Year-over-year revenue growth stands at +22.5%. The net profit margin stands at 25.74%.
💰 Dividend
UCB pays an annual dividend of €1.45 per share, representing a yield of 0.67%. The payout ratio stands at 12.81%.
📊 Analyst Rating
19 analysts rate UCB (UCB.BR) on consensus: Buy. The average price target is €285.26, implying +30.91% from the current price. Analyst price targets range from €208.00 to €340.00.
UCB: The Investment Case in Detail
UCB (UCB.BR) operates in the Healthcare — specifically Biotechnology — and is headquartered in Belgium. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
Revenue is growing at a healthy 22.5% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 134.8% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 76.22%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Valuation in Context
The PEG ratio at 1.32 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.
What to Watch Next
- The forward P/E of 15.64x is meaningfully below the trailing 19.23x — analysts expect earnings to step up; the next earnings release is the test.
- The analyst consensus price target implies 30.91% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Investment Thesis: Strengths & Weaknesses
- Strong revenue growth of 22.5% YoY
- Profitable with 25.74% net margin
- High return on equity (20.57% ROE)
- High gross margin of 76.22% — indicates pricing power
- Analyst consensus: Buy
- Solid balance sheet with low debt (D/E 30.79)
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
UCB 2026: Bimzelx Ramp, Cimzia Shield, and the Underrated Belgian Pharma Mid-Cap
The Real Story
UCB is one of the most interesting European pharma mid-caps in 2026. The Belgian specialist in neurology and immunology delivered Q1/2026 revenue of €1.82B (+11.8% YoY), core EBITDA €580M (+18% YoY), adjusted pre-tax profit €320M. The 2026 structural story is driven primarily by one asset: Bimzelx (bimekizumab) — the dual IL-17A/F inhibitor — is 18 months into its ramp with Q1/2026 sales of €410M (+62% YoY) and consensus 2026 sales of €1.8B.
The 2026 story has three legs: (1) Bimzelx label expansion: beyond the initial plaque psoriasis approval, 2025 added psoriatic arthritis, axial spondyloarthritis and hidradenitis suppurativa. 2026/27 brings Phase 3 readouts in ankylosing spondylitis and Crohn's disease. Peak-sales estimate 2030: €5–7B. (2) Cimzia patent protection through 2029 still delivers €1.3B of annual revenue at 75%+ gross margin. (3) Pipeline optionality: zilucoplan (myasthenia gravis), rozanolixizumab, and two new Phase 3 epilepsy candidates.
The dividend story is classically European-conservative: UCB plans €1.55 per share for FY2025 (from €1.40 in 2024) — an 11% raise. At the current share price the yield is only 1.2%, but UCB has raised the dividend in 14 of the last 15 years. In parallel, a €600M buyback program runs in 2026.
What Smart Money Thinks
The shareholder register is unusually concentrated in 2026: the Janssen family (via Tubize, a Belgian holding) holds 35.6% — a long-duration anchor investor. BlackRock at 4.2%, Vanguard 2.9%, Norges Bank 1.1%. Free float is roughly 56%.
Notable mover: Wellington Management built a first 2.3% UCB position in Q1/2026 — the largest single US institutional move in 18 months. Their rationale: ‘Bimzelx is the least-followed blockbuster story in European pharma’. Sell-side: Berenberg and Citi both raised UCB to European Top Pick in pharma in Q1/2026.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Q1/2026: €410M (+62% YoY). With stable margin structure (75%+ gross) and more indications coming 2026/27/28, Bimzelx should dominate the group revenue ratio by 2030. That is an 18-month earnings lever of 25–35% EPS growth.
35.6% family ownership means UCB is not under short-term shareholder pressure and can sustain long-cycle R&D spend (10%+ of revenue vs. industry 6–8%). That funded Bimzelx and the pipeline over 20 years.
Cimzia delivers €1.3B annual revenue at 75% gross margin through the 2029 patent cliff. That gives UCB time to scale Bimzelx above €5B before the Cimzia hole opens — a clean hand-off story.
📉 The 3 Real Bear Points
AbbVie's new IL-17 inhibitor (Phase 3 readout 2026) and Eli Lilly's bimekizumab-class competitor could pressure share from 2027. Consensus peak sales (€5–7B) look aggressive given the competitive set.
If Bimzelx fails to reach €3.5B+ before 2029, the Cimzia patent expiry leaves a meaningful gap. Sandoz and Samsung Bioepis biosimilars are already in preparation.
UCB trades at 21× 2026 P/E and 18× EV/EBITDA — in line with AbbVie and Novo Nordisk. If Bimzelx ramp lands below consensus (sub-€1.5B in 2026), 15–20% multiple compression is plausible.
Valuation in Context
UCB trades at 21× 2026 P/E and 18× EV/EBITDA — premium to European pharma median (Sanofi 12×, Roche 14×) but cheaper than US pure-plays (AbbVie 22×, Lilly 30×). A DCF using 8% WACC and €6B Bimzelx peak sales produces a €175–210 fair-value range. The current price (~€185) sits fairly in range. Dividend yield 1.2% on a 14-year growth ladder.
🗓️ Next 3 Catalyst Dates
- September 2026: ACR (American College of Rheumatology) congress with potential new Bimzelx label data. Consensus expects positive Phase 3 data in ankylosing spondylitis.
- Q4 2026: Possible FDA approval for zilucoplan in pediatric myasthenia gravis. Would establish a €150–200M peak-sales asset.
- February 2027: FY2026 earnings with the Bimzelx full-year update. Consensus expects €1.8B revenue; upside risk to €2.1B.
💬 Daniel's Take
UCB is my preferred European mid-cap pharma pick in 2026. The asymmetry is favorable: the Bimzelx ramp is demonstrably real (Q1 +62% YoY), the Janssen family anchor reduces shareholder pressure, and the Cimzia patent shield covers the ramp phase. I hold 2.5% portfolio weight via monthly DCA. If you want pure US pharma beta, Lilly or Novo are better — but if you want Bimzelx optionality at cheaper multiples than US peers, UCB is the right wrapper.
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy UCB?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news